Call Options

20 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.82 - $6.93 $207,260 - $297,990
43,000 Added 21.5%
243,000 $1.26 Million
Q4 2023

Feb 14, 2024

BUY
$5.63 - $8.27 $294,449 - $432,521
52,300 Added 35.41%
200,000 $1.35 Million
Q3 2023

Nov 14, 2023

SELL
$6.71 - $11.83 $1.61 Million - $2.84 Million
-240,000 Reduced 61.9%
147,700 $991,000
Q1 2023

May 15, 2023

SELL
$18.7 - $23.07 $15 Million - $18.5 Million
-800,000 Reduced 67.36%
387,700 $7.81 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $3.4 Million - $5.13 Million
187,700 Added 18.77%
1,187,700 $26.9 Million
Q3 2022

Nov 10, 2022

BUY
$16.98 - $25.54 $3.4 Million - $5.11 Million
200,000 Added 25.0%
1,000,000 $18.8 Million
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $1.18 Million - $1.84 Million
-90,000 Reduced 10.11%
800,000 $14.9 Million
Q1 2022

May 13, 2022

SELL
$14.54 - $21.5 $17.7 Million - $26.1 Million
-1,215,900 Reduced 57.74%
890,000 $16.1 Million
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $18.2 Million - $22.5 Million
605,900 Added 40.39%
2,105,900 $64.9 Million
Q1 2021

May 14, 2021

BUY
$29.24 - $42.03 $11.3 Million - $16.3 Million
387,500 Added 34.83%
1,500,000 $50.5 Million
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $1.77 Million - $2.53 Million
50,000 Added 4.71%
1,112,500 $40.2 Million
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $6.76 Million - $10.2 Million
150,000 Added 16.44%
1,062,500 $47.9 Million
Q1 2020

May 14, 2020

SELL
$40.01 - $73.97 $9.7 Million - $17.9 Million
-242,500 Reduced 21.0%
912,500 $43.3 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $30.1 Million - $60.4 Million
-810,000 Reduced 41.22%
1,155,000 $82.8 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $15.3 Million - $29.8 Million
388,500 Added 24.64%
1,965,000 $77.3 Million
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $19.9 Million - $30.9 Million
376,500 Added 31.37%
1,576,500 $123 Million
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $2.74 Million - $6.84 Million
100,000 Added 9.09%
1,200,000 $71.6 Million
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $16 Million - $23.8 Million
-700,000 Reduced 38.89%
1,100,000 $31.7 Million
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $28.5 Million - $51.9 Million
1,300,000 Added 260.0%
1,800,000 $68 Million
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $4.74 Million - $9.8 Million
500,000
500,000 $9.8 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.